PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPodofilox
Podofilox
Condylox, Podofilox (podofilox) is a small molecule pharmaceutical. Podofilox was first approved as Condylox on 1990-12-13. It is used to treat warts in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Condylox, Podofilox (discontinued: Podofilox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Podofilox
Tradename
Company
Number
Date
Products
CONDYLOXAllerganN-020529 RX1997-03-13
1 products, RLD, RS
CONDYLOXTevaN-019795 RX1990-12-13
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
condyloxNew Drug Application2024-01-29
podofiloxANDA2023-05-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
warts—D014860B07
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB04: Podophyllotoxin
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CB: Podophyllotoxin derivatives, antineoplastic drugs
HCPCS
No data
Clinical
Clinical Trials
145 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.925378—158
LeukemiaD007938—C9510149——29
B-cell lymphomaD016393——17182——29
Large b-cell lymphoma diffuseD016403—C83.316152——26
RecurrenceD012008——15191——26
Non-hodgkin lymphomaD008228—C85.913211——26
CarcinomaD002277—C80.07117——20
Lung neoplasmsD008175HP_0100526C34.906114——18
Lymphoid leukemiaD007945—C91397——17
Small cell lung carcinomaD055752——8101——16
Show 53 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Follicular lymphomaD008224—C8267———9
Burkitt lymphomaD002051—C83.755———8
Mantle-cell lymphomaD020522——66———8
T-cell lymphomaD016399——45———6
Large-cell lymphoma anaplasticD017728—C84.634———5
Hematologic neoplasmsD019337——31———4
Hematopoietic stem cell transplantationD018380——32———4
Plasmablastic lymphomaD000069293—C83.343———4
Large-cell lymphoma immunoblasticD016400——43———4
Myelomonocytic leukemia acuteD015479—C92.521———3
Show 76 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Megakaryoblastic leukemia acuteD007947—C94.22————2
Monocytic leukemia acuteD007948——2————2
Erythroblastic leukemia acuteD004915EFO_1001257C94.02————2
Urologic neoplasmsD014571—C64-C682————2
Neuroendocrine tumorsD018358EFO_1001901D3A.82————2
Basophilic leukemia acuteD015471—C94.81————1
Hypereosinophilic syndromeD017681EFO_1001467D72.111————1
Eosinophilic leukemia acuteD015472——1————1
Choroid plexus neoplasmsD016545EFO_0007206—1————1
MycosesD009181—B35-B491————1
Show 22 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePodofilox
INN—
Description
Podophyllotoxin is an organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing a 3,4,5-trimethoxyphenyl substituent. It is found in the roots and rhizomes of Podophyllum species and is used for the topical treatment of genital warts. It has a role as an antineoplastic agent, a keratolytic drug, a tubulin modulator, a microtubule-destabilising agent, an antimitotic and a plant metabolite. It is a furonaphthodioxole, a lignan and an organic heterotetracyclic compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
Identifiers
PDB—
CAS-ID518-28-5
RxCUI—
ChEMBL IDCHEMBL61
ChEBI ID50305
PubChem CID10607
DrugBankDB01179
UNII ID—
Target
Agency Approved
IGF1R
IGF1R
Organism
Homo sapiens
Gene name
IGF1R
Gene synonyms
NCBI Gene ID
3480
Protein name
insulin-like growth factor 1 receptor
Protein synonyms
CD221, IGF-I receptor, Insulin-like growth factor I receptor
Uniprot ID
Q9UCC0
Mouse ortholog
Igf1r (16001)
insulin-like growth factor 1 receptor (Q60751)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Podofilox
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,986 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
105 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use